Data Sheet (Cat.No.T3476)



JI-101

| Chemical Propert | ies | |
|-------------------|--|-----------|
| CAS No. : | 900573-88-8 | Pr |
| Formula: | C22H20BrN5O2 | HN |
| Molecular Weight: | 466.34 | HN O CH3 |
| Appearance: 🦲 | no data available | |
| Storage: | Powder: -20°C for 3 years In solvent: -80°C for 1 years | N H pi |
| | | |

| Biological Description | |
|-------------------------------|---|
| Description | JI-101 (CGI-1842) is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor β (PDGFR- β), and ephrin type-B receptor 4 (EphB4). |
| Targets(IC50) | VEGFR,PDGFR,Ephrin Receptor |

| Solubility Infor | mation | |
|------------------|--------|---|
| Solubility | © | DMSO: 27.5 mg/mL (58.97 mM), (< 1 mg/ml refers to the product slightly soluble or insoluble) |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 2.1444 mL | 10.7218 mL | 21.4436 mL |
| 5 mM | 0.4289 mL | 2.1444 mL | 4.2887 mL |
| 10 mM | 0.2144 mL | 1.0722 mL | 2.1444 mL |
| 50 mM | 0.0429 mL | 0.2144 mL | 0.4289 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Mark L. Wade, Neeraj Agarwal et al. A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort. Investigational New

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481